| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | VERISKIN, INC | 11839 SORRENTO VALLEY RD STE 923 | SAN DIEGO | CA | 92121-1063 | SAN DIEGO | USA | R44CA250768 | Clinical performance of hemodynamics-based non-invasive device for skin cancer testing | 000 | 2 | NIH | 1/9/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $726,013 ) |
| | 2023 | 2023 | VERISKIN INC | 10211 PACIFIC MESA BLVD | SAN DIEGO | CA | 92121-4327 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 001 | 5 | NIH | 6/21/2023 | $757,314 |
| | 2023 | 2018 | VERISKIN INC | 10211 PACIFIC MESA BLVD | SAN DIEGO | CA | 92121-4327 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 000 | 3 | NIH | 10/1/2022 | -$31,301 |
|
| Issue Date FY: 2022 ( Subtotal = $1,499,425 ) |
| | 2022 | 2022 | VERISKIN, INC. | 10211 PACIFIC MESA BLVD STE 404 | SAN DIEGO | CA | 92121-4327 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 000 | 4 | NIH | 7/14/2022 | $1,499,425 |
|
| Issue Date FY: 2021 ( Subtotal = $833,460 ) |
| | 2021 | 2021 | VERISKIN, INC. | 6640 LUSK BLVD STE A206 | SAN DIEGO | CA | 92121-2777 | SAN DIEGO | USA | R44CA250768 | Clinical performance of hemodynamics-based non-invasive device for skin cancer testing | 000 | 2 | NIH | 2/26/2021 | $833,460 |
|
| Issue Date FY: 2020 ( Subtotal = $1,164,975 ) |
| | 2020 | 2020 | VERISKIN, INC. | 6640 LUSK BLVD STE A206 | SAN DIEGO | CA | 92121-2777 | SAN DIEGO | USA | R44CA250768 | Clinical performance of hemodynamics-based non-invasive device for skin cancer testing | 000 | 1 | NIH | 3/13/2020 | $1,164,975 |
| | 2020 | 2017 | VERISKIN, INC. | 6640 LUSK BLVD STE A206 | SAN DIEGO | CA | 92121-2777 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 001 | 3 | NIH | 6/16/2020 | $0 |
| | 2020 | 2017 | VERISKIN, INC. | 6640 LUSK BLVD STE A206 | SAN DIEGO | CA | 92121-2777 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 002 | 3 | NIH | 7/10/2020 | $0 |
| | 2020 | 2017 | VERISKIN, INC. | 6640 LUSK BLVD STE A206 | SAN DIEGO | CA | 92121-2777 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 000 | 3 | NIH | 6/16/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2017 | VERISKIN, INC. | 6450 LUSK BLVD SUITE E202 | SAN DIEGO | CA | 92121-2778 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 000 | 3 | NIH | 1/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,000 ) |
| | 2018 | 2018 | VERISKIN, INC. | 6450 LUSK BLVD SUITE E202 | SAN DIEGO | CA | 92121-2778 | SAN DIEGO | USA | R44CA203038 | Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | 000 | 3 | NIH | 8/8/2018 | $2,000 |
|
| Issue Date FY: 2017 ( Subtotal = $896,929 ) |
| | 2017 | 2017 | VERISKIN, INC. | 6450 LUSK BLVD SUITE E202 | SAN DIEGO | CA | 92121-2778 | SAN DIEGO | USA | R44CA203038 | Hemodynamic Noninvasive Skin Cancer Diagnostics | 002 | 3 | NIH | 5/1/2017 | $896,930 |
| | 2017 | 2016 | VERISKIN, INC. | 6450 LUSK BLVD SUITE E202 | SAN DIEGO | CA | 92121-2778 | SAN DIEGO | USA | R44CA203038 | Hemodynamic Noninvasive Skin Cancer Diagnostics | 000 | 1 | NIH | 1/13/2017 | -$521,410 |
| | 2017 | 2016 | VERISKIN, INC. | 6450 LUSK BLVD SUITE E202 | SAN DIEGO | CA | 92121-2778 | SAN DIEGO | USA | R44CA203038 | Hemodynamic Noninvasive Skin Cancer Diagnostics | 001 | 2 | NIH | 1/18/2017 | $521,409 |
|
| Issue Date FY: 2016 ( Subtotal = $977,245 ) |
| | 2016 | 2016 | VERISKIN LLC | 4744 KESWICK CT | SAN DIEGO | CA | 92130-1337 | SAN DIEGO | USA | R44CA203038 | Hemodynamic Noninvasive Skin Cancer Diagnostics | 000 | 1 | NIH | 4/27/2016 | $977,245 |
|
|
